A functional cure for chronic hepatitis B (CHB) is defined as the sustained loss of hepatitis B surface antigen (HBsAg) with or without the appearance of anti-HBs antibodies, even after the cessation of antiviral therapy. Achieving this state is the gold standard of CHB management, as it significantly reduces the risk of disease progression to cirrhosis and hepatocellular carcinoma. The GIFT project, a prospective multicentre observational study, seeks to validate the GOLDEN prediction model—a framework designed to identify which patients are most likely to achieve this clinical milestone when transitioning to combination therapy involving nucleos(t)ide analogues (NAs) and pegylated interferon (Peg-IFN) α-2b.
At Groundwork, our analysis shows that managing CHB requires a move away from indefinite viral suppression toward finite treatment strategies. While long-term NA therapy effectively suppresses HBV DNA, it rarely leads to the loss of HBsAg. The integration of Peg-IFN α-2b, an immunomodulatory agent, is critical for enhancing the host immune response to clear the virus, but it carries significant side effects and financial costs, making accurate patient selection essential.
The GOLDEN model is a predictive tool that uses sequential changes in quantitative HBsAg (qHBsAg) levels to estimate the probability of HBsAg clearance. By calculating a predictive index (Pi) based on pre-treatment viral kinetics, clinicians can categorize patients into favorable or unfavorable candidates for combination therapy. This stratification allows for a more personalized approach, potentially avoiding unnecessary interferon exposure for those unlikely to respond while intensifying monitoring for those with high clinical promise.
In the context of the GIFT project, researchers are testing whether a Pi threshold of 0.15 effectively differentiates response rates. The study aims to demonstrate that patients identified as 'favorable' under the GOLDEN model are significantly more likely to achieve HBsAg clearance after 48 weeks of combination therapy compared to those identified as 'unfavorable'.
If you are a patient receiving long-term NA therapy for chronic hepatitis B, clinical decision-making regarding treatment escalation follows a structured empirical process. The GIFT project protocol provides a blueprint for how this assessment is executed in a controlled clinical setting:
- Baseline evaluation: Before initiating combination therapy, your physician assesses your current viral load and qHBsAg levels to establish a baseline for your specific viral kinetics.
- Calculation of the predictive index (Pi): Using your longitudinal qHBsAg data, the GOLDEN model calculates your Pi score. This score mathematically reflects your likelihood of achieving HBsAg loss based on how your body has responded to previous therapy.
- Stratification: Based on the Pi score, you are categorized into a 'favorable' (Pi > 0.15) or 'unfavorable' (Pi ≤ 0.15) group. This categorization informs the expected clinical path.
- Combination treatment: Both groups undergo a standardized 48-week regimen of Peg-IFN α-2b added to ongoing NA therapy. This combination is designed to leverage the viral suppression of NAs with the immune-activating properties of interferon.
- Monitoring and endpoints: Throughout the 48 weeks, your HBsAg levels are monitored. The primary endpoint is HBsAg clearance, defined as the loss of detectable surface antigen at any point during the study period.
Keep exploring
More from GroundworkPegylated interferon α-2b is a potent drug, but it is associated with a range of adverse events, including flu-like symptoms, hematologic changes, and psychiatric effects. Because of this, it is not a first-line treatment for every patient. Groundwork’s research framework emphasizes that the clinical utility of any therapy must be balanced against its safety profile and the probability of success.
By utilizing models like GOLDEN, clinicians can move toward a 'precision medicine' approach. Data suggests that patients who do not meet a specific threshold of viral kinetic change are unlikely to benefit from the addition of interferon, meaning the risks of the drug would outweigh the clinical benefits. This model helps minimize exposure to toxic side effects while maximizing the efficiency of the healthcare system by directing resources toward patients with the highest probability of achieving a functional cure.
The GIFT project focuses on a 48-week window, but the true goal of CHB management is sustained HBsAg clearance. A 'functional cure' is only meaningful if it persists after treatment stops. The study design anticipates that the clearance rates between the favorable and unfavorable groups will differ significantly—specifically, the study is powered to detect a 35% clearance rate in the favorable group versus 20% in the unfavorable group.
It is important to note that even if you achieve HBsAg clearance during the 48-week treatment period, long-term follow-up is necessary. The medical community continues to investigate whether these patients require ongoing monitoring for potential viral reactivation or if the immune system remains capable of keeping the virus dormant indefinitely. Future research, including the analysis of inflammatory cytokine profiles, will likely provide deeper insights into the immunological mechanisms that allow some patients to achieve permanent control of the virus.
If you are currently on NA therapy, discuss the possibility of a functional cure with your hepatologist or infectious disease specialist. Ask specifically about your current qHBsAg trends and whether your profile makes you a candidate for combination therapy under emerging predictive models like GOLDEN. Do not alter your current NA regimen without professional supervision, as sudden discontinuation can lead to severe hepatitis flares.
Clinical trials like the GIFT project are currently enrolling patients in specific regions. If you are interested in participating in research, confirm with your medical provider that any prospective study is registered and has appropriate ethical oversight, such as the registration ChiCTR2500095819, to ensure your safety and the validity of the data being collected.
